Acalatinib/Acalatinib: indications, mechanism of action, usage and dosage, side effects, etc.

Indications:

For adults with mantle cell lymphoma (MCL) who have received at least one prior treatment. It also shows significant efficacy in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.

Mechanism of action:

Acotinib, as a second-generation selective inhibitor of Bruton's tyrosine kinase (BTK), is unique in that it can precisely covalently bind to BTK and thereby inhibit its activity. This high degree of selectivity allows acotinib to minimize its impact on non-target kinases when exerting its therapeutic effect, thereby improving the safety and efficacy of the treatment. In B cells, BTK signaling is an important regulator of key biological processes such as cell proliferation and transport. By inhibiting the autophosphorylation of BTK, acotinib effectively blocks the activation of B cells and the BCR downstream signaling pathway, thereby inhibiting the migration, proliferation and survival of B cell malignant tumors, bringing significant survival benefits to patients.

Compared with traditional BTK inhibitors, acotinib has a lower risk of adverse events related to off-target effects. This is mainly due to its high selectivity for BTK targets, which effectively reduces side effects caused by off-target effects, allowing patients to better tolerate treatment.

Medication method:

The recommended dose of acotinib is 100mg each time, and patients need to take it orally every 12 hours.

Side effects:

1.Gastrointestinal problems: Some patients may experience gastrointestinal discomfort symptoms such as diarrhea, nausea and vomiting after receiving acotinib treatment. These symptoms are usually related to the irritating effect of the drug on the gastrointestinal tract. Most patients will experience these symptoms in the early stages of treatment, but they tend to gradually reduce over time.

2.Risk of bleeding: Acotinib may increase the risk of bleeding in patients. This may be related to the effect of the drug on platelet function. Therefore, during the use of acotinib, patients need to pay close attention to their bleeding situation, and if abnormal bleeding occurs, they should report to the doctor in time.

3.Risk of infection: Because acotinib may affect the function of the immune system, patients may be more susceptible to infection while taking this drug. Patients are advised to avoid direct contact with sources of infection and maintain good personal hygiene habits to reduce the risk of infection.

4.Cardiovascular problems: Some patients may develop cardiovascular problems such as palpitations and arrhythmias after taking acotinib. These symptoms may be related to the drug's effects on cardiac electrophysiology. Therefore, while using acotinib, patients need to pay close attention to their cardiovascular status and seek medical treatment in time if abnormal symptoms occur.

5.Other common side effects: including headache, fatigue, rash and bruising. These symptoms are usually mild, but if they continue to worsen or affect quality of life, patients should consult their doctor promptly and seek help.

Warnings and precautions:

1.For elderly patients (≥65 years old), although there is usually no need to adjust the dose, adverse reactions should be paid close attention to. In patients with severe cardiovascular disease or renal impairment, acotinib should be used with caution and closely monitored for adverse effects.

2.Acotinib may increase the risk of bleeding. During use, patients should pay close attention to their own bleeding conditions, especially the risk of central nervous system and gastrointestinal bleeding. If abnormal bleeding occurs, you should seek medical treatment promptly and inform the doctor that you are using acotinib.

Drug interactions:

When acotinib is combined withCYP3A inhibitorsOr when inducers and gastric acid suppressants are used together, dose adjustment may be required. In addition, certain drugs such as warfarin or other vitamin K antagonists should not be used with acotinib because they may increase the risk of bleeding. While using acotinib, patients should inform their doctors about other drugs they are taking so that the doctor can adjust the treatment plan according to the specific situation.

Medication for special populations:

Pregnant and lactating women, and those with cardiovascular disease or renal insufficiency should consult a doctor before using acotinib and carefully assess the risks of medication.